Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 19/20 | 0.58 |
| ▸ | OGFRL1 | Q5TC84 | 12/20 | 0.58 |
| ▸ | OPRL1 | P41146 | 10/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304501 | 0.91 | OPRM1 (0.62) | OPRM1OGFRL1OPRL1OPRK1OPRD1 | |
| Cadaverine Tartrate SCHEMBL1303987 | 0.91 | OPRM1 (0.50) | OPRM1OGFRL1OPRL1OPRK1OPRD1 | |
| SCHEMBL4763145 | 0.83 | OPRM1 (0.41) | OPRM1OGFRL1OPRL1OPRK1OPRD1 | |
| Trifluoromethanesulfonic Acid SCHEMBL1304316 | 0.82 | OPRM1 (0.55) | OPRM1OGFRL1OPRL1OPRK1OPRD1 | |
| SCHEMBL4049796 | 0.81 | OPRM1 (0.56) | OPRM1OGFRL1OPRL1OPRK1OPRD1 | |
| SCHEMBL1304619 | 0.77 | OPRM1 (0.60) | OPRM1OGFRL1OPRL1OPRK1OPRD1 | |
| SCHEMBL2976303 | 0.77 | SMN1; SMN2 (0.44) | OPRM1OGFRL1OPRL1OPRK1OPRD1 | |
| SCHEMBL1304831 | 0.75 | OPRM1 (0.60) | OPRM1OGFRL1OPRL1OPRK1OPRD1 | |
| Citric Acid SCHEMBL4827292 | 0.74 | LMNA (0.36) | OPRM1OGFRL1OPRL1OPRK1OPRD1 | |
| SCHEMBL380074 | 0.74 | OPRM1 (1.00) | OPRM1OGFRL1OPRL1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120797-B2 | Process for preparing spirocyclic cyclohexane compounds, compositions containing such compounds and method of using such compounds | GRUENENTHAL GMBH (DE) | 2015-09-01 | — | — | US | claimed |
| EP-2062898-B1 | Spirocyclic cyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2013-10-02 | — | — | EP | claimed |
| US-7951948-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2011-05-31 | — | — | US | claimed |
| US-20100240897-A1 | Spirocyclic Cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2010-09-23 | — | — | US | claimed |
| EP-1560835-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2009-09-02 | — | — | EP | claimed |
| EP-2062898-A2 | Spirocyclic cyclohexane derivatives | Grünenthal GmbH (DE) | 2009-05-27 | — | — | EP | claimed |
| US-9862719-B2 | Process or preparing spirocyclic cyclohexane compounds, compositions containing such compounds and method of using such compounds | GRUENENTHAL GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-9862719-B2 | Process or preparing spirocyclic cyclohexane compounds, compositions containing such compounds and method of using such compounds | GRUENENTHAL GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| EP-2233487-B1 | Spirocyclic cyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2116544-B1 | Spirocyclic cyclohexane derivatives | GRUENENTHAL GMBH (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-20150322080-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds, Compositions Containing Such Compounds and Method of Using Such Compounds | ADNEURIS THERAPEUTICS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322080-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds, Compositions Containing Such Compounds and Method of Using Such Compounds | ADNEURIS THERAPEUTICS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322080-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds, Compositions Containing Such Compounds and Method of Using Such Compounds | ADNEURIS THERAPEUTICS, INC. | 2015-11-12 | — | — | US | disclosed |
| US-20090156626-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds and Methods of Using Such Compounds | GRENENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-7547707-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-7547707-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| US-7547707-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2009-06-16 | — | — | US | disclosed |
| EP-2062898-A2 | Spirocyclic cyclohexane derivatives | Grünenthal GmbH (DE) | 2009-05-27 | — | — | EP | disclosed |
| EP-2062898-A2 | Spirocyclic cyclohexane derivatives | Grünenthal GmbH (DE) | 2009-05-27 | — | — | EP | disclosed |
| US-20060004034-A1 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004034-A1 | Spirocyclic cyclohexane compounds | PKD1, PKD2, HSD17B7 | OPRM1 1225/4885OGFRL1 1871/4885OPRL1 470/4885 |
| US-20150322080-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds, Compositions Containing Such Compounds and Method of Using Such Compounds | PKD1, VKORC1, PKD2 | OPRM1 2030/4885OGFRL1 1903/4885OPRL1 1031/4885 |
| US-20100240897-A1 | Spirocyclic Cyclohexane Compounds | PKD1, PKD2, HSD17B7 | OPRM1 1225/4885OGFRL1 1871/4885OPRL1 470/4885 |
| US-20090156626-A1 | Process for Preparing Spirocyclic Cyclohexane Compounds and Methods of Using Such Compounds | PKD1, VKORC1, PKD2 | OPRM1 1881/4885OGFRL1 1971/4885OPRL1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.